絞り込み

16573

広告

Posttranscriptional modulation of TERC by PAPD5 inhibition rescues hematopoietic development in dyskeratosis congenita.

著者 Fok WC , Shukla S , Vessoni AT , Brenner KA , Parker R , Sturgeon CM , Batista LFZ
Blood.2019 Feb 06 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (2view , 0users)

Full Text Sources

Reduced levels of , the telomerase RNA component, cause dyskeratosis congenita (DC) in patients harboring mutations in TERC, PARN, NOP10, NHP2, NAF1, or DKC1. Inhibition of the non-canonical poly(A) polymerase , or the exosome RNA degradation complex, partially restores levels in immortalized DKC1 mutant cells, but it remains unknown if modulation of posttranscriptional processing of could improve hematopoietic output in dyskeratosis congenita. We used human embryonic stem cells (hESCs) with a common dyskerin mutation (DKC1_A353V), which have defective telomere maintenance and reduced definitive hematopoietic potential, to understand the effects of reducing EXOSC3 activity, or silencing PAPD5-mediated oligoadenylation, on hematopoietic progenitor specification and function in DC. Reduction of or levels in DKC1 mutant hESCs led to functional improvements in levels and telomerase activity, with concomitant telomere elongation and reduced levels of DNA damage signaling. Interestingly, the silencing of , but not , significantly restored definitive hematopoietic potential in DKC1 mutant cells. Mechanistically, we show that inhibition is sustained in differentiated CD34 cells, with a concomitant increase in mature, functional, forms of , indicating that regulation of is a potential strategy to reverse hematologic dysfunction in DC patients.
PMID: 30728146 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード